Voyager Therapeutics Inc
Company Profile
Business description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Contact
75 Hayden Avenue
LexingtonMA02421
USAT: +1 857 259-5340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
172
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
stocks
Goldman Sachs Earnings: Valuations remain stretched
stocks
Major ASX listed miners overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.40 | 13.90 | -0.15% |
| CAC 40 | 8,112.02 | 146.92 | -1.78% |
| DAX 40 | 24,959.06 | 338.07 | -1.34% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,195.35 | 39.94 | -0.39% |
| HKSE | 26,563.90 | 281.06 | -1.05% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,072.46 | 511.11 | -0.95% |
| NZX 50 Index | 13,503.31 | 76.98 | -0.57% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,827.30 | 9.30 | -0.11% |
| SSE Composite Index | 4,113.97 | 0.03 | -0.00% |